Terminal · Institutions

Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.

Kynam Capital Management, LP 13F Holdings -- Portfolio & Top Positions (2026-03-31)

Kynam Capital Management, LP (CIK 1907884) reported $1.62B across 34 reported positions in its SEC 13F filing for 2026-03-31. Largest positions: SNDX ($188.1M, 11.60%), CLDX ($185.3M, 11.43%), PCVX ($169.8M, 10.48%), COGT ($155.4M, 9.59%), VERA ($136.7M, 8.43%). Source: SEC Form 13F.

RankTickerCompanyValue% PortfolioSharesAction
1SNDXSYNDAX PHARMACEUTICALS INC$188.1M11.60%8.1MHold
2CLDXCELLDEX THERAPEUTICS INC NEW$185.3M11.43%5.8MTrimmed
3PCVXVAXCYTE INC$169.8M10.48%2.9MHold
4COGTCOGENT BIOSCIENCES INC$155.4M9.59%4.0MTrimmed
5VERAVERA THERAPEUTICS INC$136.7M8.43%3.4MTrimmed
6BEAMBEAM THERAPEUTICS INC$87.7M5.41%3.7MAdded
7TVTXTRAVERE THERAPEUTICS INC$72.0M4.44%2.4MAdded
8CTMXCYTOMX THERAPEUTICS INC.$70.6M4.35%15.0MAdded
9BCRXBIOCRYST PHARMACEUTICALS INC$54.1M3.34%5.7MTrimmed
10VRDNVIRIDIAN THERAPEUTICS INC$45.8M2.83%2.3MAdded
11CGEMCULLINAN THERAPEUTICS INC$44.3M2.73%3.1MHold
12URGNUROGEN PHARMA LTD$40.4M2.49%2.2MNew
13KALVKALVISTA PHARMACEUTICALS INC$36.7M2.26%1.8MAdded
14APLSAPELLIS PHARMACEUTICALS INC$33.2M2.05%825,000Trimmed
15LEGNLEGEND BIOTECH CORP$28.5M1.76%1.6MNew
16MBXMBX BIOSCIENCES INC$27.9M1.72%934,799Hold
17IMCRIMMUNOCORE HLDGS PLC$26.7M1.65%884,937Added
18STROSUTRO BIOPHARMA INC$21.7M1.34%872,558Added
19RVMDREVOLUTION MEDICINES INC$20.2M1.24%207,500New
20BNRBURNING ROCK BIOTECH LTD$19.8M1.22%1.2MAdded
21SLNOSOLENO THERAPEUTICS INC$18.7M1.16%560,000New
22NRIXNURIX THERAPEUTICS INC$18.5M1.14%1.2MTrimmed
23PHVSPHARVARIS N V$18.1M1.12%640,395Hold
24EVOMMUNE INC$14.4M0.89%625,496Added
25RLAYRELAY THERAPEUTICS INC$14.2M0.87%1.4MHold

Source: SEC Form 13F filings · as of 2026-03-31